

拍動流下における小柄患者用補助人工心臓の耐久性試験装置の開発（口演）	西田正浩, 小阪亮, 丸山 修, 山根隆志, 巽英介, 妙中義之	日本人工臓器学会大会 (52)	2014. 10. 17-19	国内
非接触軸受による次世代型補助人工心臓の課題（口演）	築谷朋典, 水野敏秀, 武輪能明, 巽 英介, 妙中義之	日本人工臓器学会大会 (52)	2014. 10. 17-19	国内
長期ECMO後の膜型人工肺内血栓付着状態の評価に関する検討（口演）	片桐伸将, 巽英介, 武輪能明, 水野敏秀, 築谷朋典, 妙中義之	日本人工臓器学会大会 (52)	2014. 10. 17-19	国内
定常流型左室補助人工心臓に併用する自己心拍同期回転数制御システムが術後慢性期に心拍数に及ぼす影響（ポスター）	伊達数馬, 西村隆, 武輪能明, 岸本 諭, 荒川衛, 岸本祐一郎, 梅木昭秀, 安藤政彦, 水野敏秀, 築谷朋典, 小野 稔, 巽 英介	日本人工臓器学会大会 (52)	2014. 10. 17-19	国内
国立循環器病研究センターにおける医療機器開発時の非臨床試験に対する信頼性保証動物試験体制の構築（ポスター）	水野敏秀, 稲垣悦子, 中野 敦, 船山麻理菜, 岩田倫明, 築谷朋典, 武輪能明, 巽 英介, 北風政史	日本人工臓器学会大会 (52)	2014. 10. 17-19	国内
革新的医療機器開発のためのガイドライン策定に向けて一産官学連携による取組み（ポスター）	中田はる佳, 赤川英毅, 築谷朋典, 水野敏秀, 武輪能明, 巽英介	日本人工臓器学会大会 (52)	2014. 10. 17-19	国内
左心補助人工心臓装着後の右心不全に対する心房内シャントの有用性（口演）	齋藤友宏, 戸田宏一, 三隈裕輔, 武輪能明, 片桐伸将, 大沼健太郎, 住倉博仁, 藤井 豊, 角田幸秀, 花田繁, 水野敏秀, 築谷朋典, 巽英介	日本人工臓器学会大会 (52)	2014. 10. 17-19	国内
補助循環中の高酸素管理が生体に及ぼす影響—小動物補助循環モデルを用いた検討—（口演）	藤井 豊, 白井幹康, 武輪能明, 巽 英介	日本人工臓器学会大会 (52)	2014. 10. 17-19	国内
5軸制御磁気浮上モータを用いた乳幼児、小児用補助人工心臓の開発（口演）	長 真啓, 増澤徹, 大森直樹, 巽 英介	日本人工臓器学会大会 (52)	2014. 10. 17-19	国内
Avalon Elite ダブルルーメンカテーテルを用いた V-V ECMOにおける酸素化効率の in vivo 検討（ポスター）	東郷好美, 武輪能明, 片桐伸将, 藤井 豊, 田邊久美, 宮本裕治, 巽 英介	日本人工臓器学会大会 (52)	2014. 10. 17-19	国内

体外設置式補助人工心臓用小型ポータブル駆動装置の開発(ポスター)	大沼健太郎, 住倉博仁, 本間章彦, 築谷朋典, 武輪能明, 水野敏秀, 向林 宏, 片野一夫, 小嶋孝一, 妙中義之, 巽 英介	日本人工臓器学会大会(52)	2014. 10. 17-19	国内
体外設置式補助人工心臓用モニタリングシステムの開発(ポスター)	大沼健太郎, 住倉博仁, 本間章彦, 築谷朋典, 武輪能明, 水野敏秀, 妙中義之, 片野一夫, 小嶋孝一, 向林 宏, 巽 英介	日本人工臓器学会大会(52)	2014. 10. 17-19	国内
アカデミアからみた医療機器開発での課題とアプローチ事例ー知的財産への評価指標を用いた公的機関の承継プロセスへの実装ー(口演)	赤川英毅, 巽英介, 大藤康一郎, 長谷川周平, 中田はる佳, 岩田倫明, 妙中義之	日本人工臓器学会大会(52)	2014. 10. 17-19	国内
右心補助を目指した定常流型左室補助人工心臓による心拍同期回転数制御システムの開発(口演)	荒川 衛	日本人工臓器学会大会(52)	2014. 10. 17-19	国内
動圧浮上型軸流ポンプを用いた補助人工心臓システムの開発(口演)	築谷朋典, 水野敏秀, 武輪能明, 巽 英介, 妙中義之	日本定常流ポンプ研究会2014	2014. 10. 17	国内
小柄患者用補助人工心臓の開発(口演)	築谷朋典, 水野敏秀, 武輪能明, 巽 英介, 妙中義之	日本機械学会2014年度年次大会	2014. 9. 7-10	国内

2. 学会誌・雑誌等における論文掲載

掲載した論文（発表題目）	発表者氏名	発表した場所 （学会誌・雑誌等名）	発表した時期	国内・外の別
In-body tissue-engineered aortic valve (Biovalve type VII) architecture based on 3D printer molding	Nakayama Y, Takewa Y, Sumikura H, Yamanami M, Matsui Y, Oie T, Kishimoto Y, Arakawa M, Ohmuma K, Tajikawa T, Kanda K, Tatsumi E	J Biomed Mater Res B Appl Biomater	2015. 1	国外
Improvement of two-stage centrifugal blood pump for cardiopulmonary support system and evaluation of anti-hemolysis performance	Horiguchi H, Tsukiya T, Takemika T, Nomoto T, Tsujiimoto Y	Int J Fluid Machinery and Systems	2015. 1	国外
A novel small animal extracorporeal circulation model for studying pathophysiology of cardiopulmonary bypass	Fujii Y, Shirai M, Inamori S, Takewa Y, Tatsumi E	J Artif Organs	2015. 3	国内
In situ observation and enhancement of leaflet tissue formation in bioprosthetic "biovalve"	Funayama M, Takewa Y, Oie T, Matsui Y, Tatsumi E, Nakayama Y	J Artif Organs	2015. 3	国内
Journal of Artificial Organs 2014: the year in review	Sawa Y, Matsuda K, Tatsumi E, Tsukiya T, Matsumiya G, Abe T, Fukunaga K, Kishida A, Kokubo K, Masuzawa T, Myoui A, Nishimura M, Nishimura T, Nishinaka T, Okamoto E, Tokunaga S, Tomo T, Yagi Y, Yamaoka T	J Artif Organs	2015. 3	国内

Sutureless aortic valve replacement using a novel autologous tissue heart valve with stent (stent biovalve): proof of concept	Kishimoto S, Takewa Y, Nakayama Y, Date K, Sumikura H, Moriwaki T, Nishimura M, Tatsumi E	J Artif Organs	2015. 1. 21 published online	国内
Development of self-expanding valved stents with autologous tubular leaflet tissues for transcatheter valve implantation	Funayama M, Sumikura H, Takewa Y, Tatsumi E,	J Artif Organs	2015. 2. 12 published online	国内
Investigation of the effects of artificial perfusion using rat extracorporeal circulation model	Fujii Y, Shirai M, Inamori S, Takewa Y, Tatsumi E	Conf Proc IEEE Med Biol Soc 2014	2014. 8	国外
Application of a search algorithm using stochastic behaviors to autonomous control of a ventricular assist device	Ohnuma K, Sumikura H, Homma A, Tsukiya T, Mizuno T, Takewa Y, Tatsumi E	Conf Proc IEEE Med Biol Soc 2014	2014. 8	国外
Novel control system to prevent right ventricular failure induced by rotary blood pump	Arakawa M, Nishimura T, Takewa Y, Umeki A, Ando M, Kishimoto Y, Fujii Y, Kyo S, Adachi H, Tatsumi E	J Artif Organs	2014. 6	国内
Alternation of left ventricular load by a continuous-flow left ventricular assist device with a native heart load control system in a chronic heart failure model	Arakawa M, Nishimura T, Takewa Y, Umeki A, Ando M, Adachi H, Tatsumi E	J Thoracic Cardiovasc Surg	2014. 8	国内
Study on development of two-stage centrifugal blood pump for cardiopulmonary support system	Horiguchi H, Tsukiya T, Nomoto T, Takemika T, Tsujimoto Y	Int J Fluid Machinery and Systems	2014. 1	国外
Development of a flow rate monitoring method for the wearable ventricular assist device driver	Ohnuma K, Homma A, Sumikura H, Tsukiya T, Takewa Y, Mizuno T, Mukaibayashi H, Kojima K, Katano K, Taenaka Y, Tatsumi E	J Artif Organs	2014. 12. 13 published online	国内

Impact of bypass flow rate and catheter position in veno-venous extracorporeal membrane oxygenation on gas exchange in vivo	Togo K, Takewa Y, Katagiri N, Fujii Y, Kishimoto S, Date K, Miyamoto Y, Tatsumi E	J Artif Organs	2014. 12. 5 published online	国内
Alternative approach for right ventricular failure after left ventricular assist device placement in animal model	Saito T, Toda K, Takewa Y, Tsukiya T, Mizuno T, Taenaka Y, Tatsumi E	Eur J Cardiothorac Surg	2014. 10. 7 published online	国外
Clinical experience of more than 2 months usage of extracorporeal membrane oxygenation (Endumo((R))4000) without circuit exchange	Kusajima K, Hoashi T, Kagisaki K, Yoshida K, Nishigaki T, Hayashi T, Ichikawa H	J Artif Organs	2014. 3	国内
小児用補助人工心臓のための小型磁気浮上モータの第一試作	大森直樹, 増澤徹, 長真啓, 巽英介	日本AEM学会誌	in press	国内
ECMOデバイスの現状と将来	巽英介	救急・集中治療	2014. 9	国内
人工心臓(基礎)	水野敏秀	人工臓器	2014. 12. 15	国内
耐久性試験装置(ラボハートNCVC)の開発とその応用例	住倉博仁, 大沼健太郎, 本間章彦, 妙中義之, 武輪能明, 築谷朋典, 水野敏秀, 向林宏, 小嶋孝一, 巽英介	循環器病研究の進歩	2014. 11. 30	国内
小児用人工心臓のための小型5軸制御セルフベアリングモータ	長真啓, 増澤徹, 大森直樹, 巽英介	日本AEM学会誌	2014. 6	国内
遠心型ポンプと軸流型ポンプ	築谷朋典	人工臓器	2014. 6. 15	国内

# Investigation of the biological effects of artificial perfusion using rat extracorporeal circulation model

Yutaka Fujii, Mikiyasu Shirai, Shuji Inamori, Yoshiaki Takewa and Eisuke Tatsumi

**Abstract**— Extracorporeal circulation (ECC) is indispensable for cardiac surgery. Since difficulty in clinical research keeps the knowledge insufficient, it is desirable to have a miniature ECC system for small animals. We aimed to establish a miniature ECC system and apply the system to the rat for investigating biochemical changes. The ECC system consisted of a membranous oxygenator (polypropylene, 0.03 m<sup>2</sup>), tubing line (polyvinyl chloride) and roller pump. Priming volume of this system is only 15 ml. Rats were divided into the SHAM group and the ECC group. ECC pump flow was initiated and maintained at 70 ml/kg/min. We measured the serum cytokine levels of tumor necrosis factor- $\alpha$ , interleukin (IL)-6, and IL-10, and biochemical markers (lactate dehydrogenase, aspartate aminotransferase and alanine aminotransferase) before, 60, and 120 min after the initiation of ECC. In addition, we measured the wet-to-dry weight (W/D) ratio of the left lung tissues. During ECC, blood pressure and Hb were maintained around 80 mmHg and 10g/dl, the serum cytokine levels and biochemical markers were significantly elevated in the ECC group compared with the SHAM group. The W/D ratio increased significantly more in the ECC group compared with that in the SHAM group. These data suggest that ECC promotes organ damages and systemic inflammatory response. This rat ECC model is considered to be equivalent to the already established human ECC and useful for studying the mechanism of pathophysiological changes during artificial perfusion.

## I. INTRODUCTION

Extracorporeal circulation (ECC) is indispensable for cardiac surgery [1]. Despite the fact that ECC is traumatic to blood components and non-physiologic, its influence has not been fully elucidated. Since difficulty in clinical research and animal experiments keeps the knowledge insufficient, it is desirable to have a miniature ECC system for small animals to study the mechanism of pathophysiological changes in the circulation during ECC. Therefore, in this study, we measured the serum cytokine levels of tumor necrosis factor- $\alpha$ , interleukin (IL)-6, and IL-10, and biochemical markers (lactate dehydrogenase, aspartate aminotransferase and alanine aminotransferase) before, 60, and 120 min after the initiation of CPB. In addition, we measured the wet-to-dry weight (W/D) ratio of the left lung tissues.

Yutaka Fujii, Mikiyasu Shirai, Yoshiaki Takewa, and Eisuke Tatsumi are with the National Cerebral & Cardiovascular Center Research Institute, 5-7-1, Fujishiro-dai, Suita, Osaka, 565-8565, Japan (phone: 81-6-6833-5012; fax: 81-6-6835-5416; e-mail: yfujii@ncvc.go.jp).

Shuji Inamori is with the Hiroshima International University, 555-36, Kurosegakuendai, Higashihiroshima, Hiroshima, 739-2631, Japan.

## II. MATERIALS AND METHODS

### A. Animal

The study was approved by the National Cerebral and Cardiovascular Center Research Institute Animal Care and Use Committee, and all procedures met the National Institutes of Health guidelines for animal care.

Sprague-Dawley rats (male 400-450 g) were housed three per cage under a 12-h light-dark cycle with food and water available ad libitum.

### B. Anesthesia, surgical preparation, and ECC

The animals were anesthetized with pentobarbital sodium (50 mg/kg body weight, intraperitoneal injection) and placed in the supine position with rectal thermocouple in place. Then, orotracheal intubation was performed using a 14G cannula (Insyte BD Medical, Sandy, UT, USA) and rats were ventilated with a respirator (Model SN-480-7, Shinano Seisakusho Co., Ltd, Tokyo, Japan). Ventilation was volume controlled at a frequency of 70/min, a tidal volume of 8-10 mL/kg body weight, and 40 % of inspired oxygen fraction. Rectal temperature was maintained at 36 °C throughout the experiment. Arterial blood pressure was monitored (Model 870, PowerLab system, AD Instruments, Castle Hill, NSW, Australia) via the femoral artery, which was cannulated with polyethylene tubing (SP-31 Natsume Seisakusho Co., Ltd, Tokyo, Japan). The left common carotid artery with a polyethylene tubing (SP-55 Natsume Seisakusho Co.) to serve as the arterial inflow cannula for the ECC circuit. 500 IU/kg heparin sodium was administered after placement of this cannula. A 16 G cannula (Insyte BD Medical) was advanced through the right external jugular vein into the right atrium and served as a conduit for venous outflow.




Figure 1. The small animal ECC system.

The ECC circuit consisted of a membranous oxygenator (Senko Medical Co., Ltd, Osaka, Japan), tubing line (Senko Medical Co., Ltd) and roller pump (Micro tube pump MP-3 Tokyo Rikakikai Co., Ltd, Tokyo, Japan). The ECC circuit was primed by 14 ml of Ringer's solution bicarbonate and 1 ml (1000 IU) of heparin, total priming volume was 15 ml (Fig.1). Figure 2 shows the small animal ECC model schema.

### C. Experimental design

The animals were divided into two groups: SHAM group (n=5), ECC group (n=7). The SHAM group received surgical preparation only without ECC. ECC pump flow was initiated and maintained at 70 mL/kg/min. Arterial pressure of carbon dioxide (PaO<sub>2</sub>) and arterial pressure of oxygen (PaO<sub>2</sub>) were maintained at 35-45 mmHg and 300-400 mmHg, respectively. Blood samples were collected at three defined time points, before ECC (pre-ECC), 60 min after initiation of ECC and 120 min after initiation of ECC (end-ECC).

To evaluate the inflammatory responses, TNF- $\alpha$ , IL-6, and IL-10 were measured (ELISA kit, R&D Systems, Minneapolis, MN, USA). The biochemical markers for evaluating organ damage (17), LDH, AST, and ALT were measured (DRI-CHE M 7000, Fujifilm, Kanagawa, Japan). Blood gases, pH, hemoglobin concentration, and electrolytes were also measured. Animals in which the hemoglobin level declined to less than 7 g/dL at any point were excluded from the study. All animals were sacrificed at the end of ECC by myocardial potassium injection and the left lung was harvested and divided into three parts. The superior third was used for the calculation of W/D ratio. The lung block was weighed before and after desiccation for 72 h in a drying oven at 70°C.




Figure 2. The small animal ECC model schema.

### D. Statistics

All data are expressed as mean  $\pm$  standard deviation. Comparison among groups was performed using analysis of variance. Fisher Protected Least Significant Difference post hoc test was used for subsequent comparison between groups at the same time. All statistical analyses were performed using Stat-View 5.0 (Abacus Concepts, Berkeley, CA, USA). Significance was set at  $P < 0.05$ .

## III. RESULTS

Table 1 shows the changes in hemodynamic variables, Hb concentration and PaO<sub>2</sub> and PaCO<sub>2</sub> in SHAM and ECC groups during experiments. Mean arterial pressure (MAP) and Hb were significantly decreased during experiment in ECC groups.

TABLE I. HEMODYNAMIC VARIABLES, Hb AND BLOOD GAS PARTIAL PRESSURES BEFORE AND DURING ECC

	Group	Pre-ECC	ECC 60 min	ECC 120 min
MAP (mmHg)	SHAM	103 $\pm$ 3	100 $\pm$ 5	104 $\pm$ 3
	ECC	105 $\pm$ 5	80 $\pm$ 3 †	76 $\pm$ 3 †
HR (beat/min)	SHAM	385 $\pm$ 15	385 $\pm$ 11	381 $\pm$ 7
	ECC	406 $\pm$ 9	358 $\pm$ 8	363 $\pm$ 8
PaO <sub>2</sub> (mmHg)	SHAM	113 $\pm$ 8	106 $\pm$ 7	105 $\pm$ 6
	ECC	103 $\pm$ 8	464 $\pm$ 17 †	461 $\pm$ 16 †
PaCO <sub>2</sub> (mmHg)	SHAM	38 $\pm$ 1	37 $\pm$ 1	40 $\pm$ 1
	ECC	40 $\pm$ 1	37 $\pm$ 1	36 $\pm$ 1
Hb (mg/dL)	SHAM	15.3 $\pm$ 1.0	15.2 $\pm$ 0.5	14.5 $\pm$ 0.4
	ECC	15.4 $\pm$ 0.2	10.1 $\pm$ 0.5 †	9.8 $\pm$ 0.4 †

Variables are expressed by mean  $\pm$  standard error.  
†  $P < 0.05$  versus SHAM group at the same time.




Figure 3. Serum TNF- $\alpha$  (a), IL-6 (b), IL-10 (c), LDH (d), AST (e), ALT (f).  
†  $P < 0.05$  versus SHAM group at the same time periods.

The PaO<sub>2</sub> level was much higher in the ECC group (~460 mmHg) than in the SHAM group (~130 mmHg), while no statistical difference was found in the PaCO<sub>2</sub> level between these groups.




Figure 4. Wet to dry ratio of left lung at the end of ECC.  
†  $P < 0.05$  versus SHAM group

Before ECC, the serum levels of inflammatory and biochemical markers were not statistically different among the SHAM and ECC groups. Serum inflammatory and biochemical markers remained unchanged during experiment periods in the SHAM group. In the ECC group, the cytokines and increased significantly, reaching a maximum (TNF- $\alpha$  : 1237  $\pm$  62 pg/ml, IL-6 : 1695  $\pm$  73 pg/ml, IL-10: 632  $\pm$  40 pg/ml) at the end of ECC (Fig. 3a-c)

In the ECC group, the levels of biochemical markers significantly increased (LDH : 447 $\pm$ 48 U/L, AST : 143 $\pm$ 12 U/L, ALT : 46 $\pm$ 7 U/L) 60 min after the ECC initiation and increased further (LDH : 882 $\pm$ 62 U/L, AST : 233 $\pm$ 20 U/L, ALT : 92 $\pm$ 11 U/L) 120 min after the ECC initiation (Fig. 3d-e).

The ECC groups showed significantly higher W/D ratio than the SHAM group. (SHAM group : 4.68 $\pm$ 0.08, ECC group : 6.01 $\pm$ 0.10) (Fig.4).

#### IV. DISCUSSION

In this study, our small animal ECC system was able to maintain adequate levels of blood gases (PaCO<sub>2</sub>:35-45 mmHg, PaO<sub>2</sub>: 300-400 mmHg), Hb (around the 10 g/dl level) and blood pressure (Mean arterial pressure more than 70 mmHg). Previous models have required high priming volumes to achieve acceptable hematocrit concentrations during the experiment. On the other hand, our model offers the advantage of a low priming volume not requiring transfusion in ECC group rats. Most previous research was performed in isolated heart models (e.g., Langendorff's method) [2]. By using our small animal ECC model, due to its minimal invasiveness and ease of recoverability, short- and long-term effects of ECC time, temperature (hypothermic condition), blood contact surface area and potentially also direct gene transfer on myocardial function and histological outcomes can be assessed better than in isolated heart models. While these

models allow investigating the immediate effects of therapeutic interventions or different cardioplegia solutions, they preclude the assessment of long-term histological, biochemical, or functional outcomes. Survival studies using dogs or pigs [3,4] have been performed but are limited due to sample size and costs.

The present data showed that during the serum cytokine levels (TNF- $\alpha$ , IL-6 and IL-10) and biochemical markers (LDH, ALT, AST) were significantly elevated in the ECC group compared with the SHAM group, indicating that organ damage and a systemic inflammatory response occurred in our rat ECC model. During ECC, blood pressure and Hb were maintained around 80 mmHg and 10 g/dl, respectively. From these data, our rat ECC model is considered to be equivalent to the established human ECC, which is often associated with systemic inflammation and organ damage [5-7].

The significant systemic inflammatory responses occurred, reaching a maximum at the end of ECC. Additionally, the biochemical markers reflecting organ damages significantly increased 60 min after the ECC initiation and increased further 120 min after the ECC initiation. The significant increase in the W/D ratio which suggests pulmonary edema [8] is consistent with the previous clinical data [9]. From these data, our rat ECC model is considered to be equivalent to the established human ECC, which is often associated with systemic inflammation and organ damage [10].

It has been suggested that the factors responsible for the inflammatory response during ECC are blood contact with the surface of the extracorporeal circulation unit, endotoxemia, surgical trauma, ischemic reperfusion injury, and blood loss [11]. Many studies showed the walls of the ECC circuit activate white cells, platelets and the complement system. The increase in cytokines, such as interleukins and necrosis factor [12], aggravates the inflammatory response [13]. These complex interactions during ECC lead to further inflammation [13]. In our rat ECC models, the insufflation of hydrogen which selectively reduces the hydroxyl radical could decrease the levels of serum cytokines and biochemical markers, and the W/D ratio of the lung, suggesting that this radical contributes toward promoting the systemic inflammatory responses and organ damages during ECC [8].

Our previous study showed the selective reduction of hydroxyl radical with hydrogen gas attenuates both pro- and anti-inflammatory cytokines, suggesting that this radical acts to non-selectively increase these cytokines [8]. In addition, our new finding is that this increase in the W/D ratio was attenuated with hydrogen gas insufflation. Because ECC increases pulmonary vascular permeability, it is possible that hydrogen gas insufflation attenuates the injury of pulmonary vascular endothelium by scavenging reactive oxygen species and reducing the increase in vascular permeability during ECC. Although the detailed mechanism of the abovementioned anti-inflammatory effects of hydrogen gas insufflation was not elucidated in the previous study[8], this treatment may potentially serve as a novel clinical intervention in reducing the ECC-induced systemic inflammation. Solution of the inflammation mechanism during ECC require future research.



We have to study of due to its minimal invasiveness and ease of recoverability, short- and long-term effects of ECC time, temperature (hypothermic condition), blood contact surface area and potentially also direct gene transfer on myocardial function and histological outcomes. In addition, the model allows for the investigation of unique animal strains with varying susceptibility to myocardial injury depending on either their genetic background or disease (e.g., diabetes, old age, hypertension).

There are some limitations to this current model. Although our model closely resembles current clinical standards with respect to the ECC circuit, a number of potentially important differences to the clinical setting are present. Median sternotomy, direct surgery on the heart involving aortic cross-clamping, and cardiac arrest with the use of cardioplegia were not performed. Similarly, the absence of significant atheromatous disease and the complex comorbidities seen in patients undergoing coronary artery bypass graft surgery are limitations.

#### V. CONCLUSION

In this study, we developed a miniature ECC model and applied the system to the rat. In our rat ECC models, we demonstrated that adequate levels of blood gases and Hb, and blood pressure were maintained and that the systemic inflammatory response and organ damages including pulmonary edema were induced associated with the production of cytokines. We considered that our rat ECC model is equivalent to the established human ECC, which is often associated with systemic inflammation and organ damage. This miniature ECC model could be a very useful approach for studying the mechanism of pathophysiology during ECC and basic assessment of the ECC devices.

#### ACKNOWLEDGMENT

This work was supported by JSPS KAKENHI Grant Number 25871231 (Grant-in-Aid for Young Scientists B).

#### REFERENCES

- [1] Walker G, Liddell M, Davis C. Extracorporeal life support-state of the art. *Paediatr Respir Rev* 2003;4:147-52.
- [2] Bopassa JC, Vandroux D, Ovize M, Ferrera R: Controlled reperfusion after hypothermic heart preservation inhibits mitochondrial permeability transition-pore opening and enhances functional recovery. *Am J Physiol Heart Circ Physiol* 2006, 291(5):H2265-71.
- [3] Schmidt FE Jr., MacDonald MJ, Murphy CO, Brown WM 3rd, Gott JP, Guyton RA: Leukocyte depletion of blood cardioplegia attenuates reperfusion injury. *Ann Thorac Surg* 1996, 62(6):1691-6; discussion 1696-7.
- [4] Fischer UM, Klass O, Stock U, Easo J, Geissler HJ, Fischer JH, Bloch W, Mehlhorn U: Cardioplegic arrest induces apoptosis signal pathway in myocardial endothelial cells and cardiac myocytes. *Eur J Cardiothorac Surg* 2003, 23(6):984-990.
- [5] Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory response to cardiac surgery: Implications for the anesthesiologist. *Anesthesiology* 2002;97:215-52.
- [6] Boyle EM, Pohlman TH, Johnson MC, Verrier ED. Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. *Ann Thorac Surg* 1997;63: 277-84.
- [7] Takahashi Y, Shibata T, Sasaki Y, Fujii H, Ikuta T, Bito Y, Nakahira A, Suehiro S. Impact of non-di-(2-ethylhexyl) phthalate cardiopulmonary bypass tubes on inflammatory cytokines and coagulation-fibrinolysis systems during cardiopulmonary bypass. *J Artif Organs* 2009;12:226-31.
- [8] Fujii Y, Shirai M, Inamori S, Shimouchi A, Sonobe T, Tsuchimochi H, Pearson JT, Takewa Y, Tatsumi E, Taenaka Y. et al. Insufflation of Hydrogen Gas Restrains the Inflammatory Response of Cardiopulmonary Bypass in a Rat Model. *Artif Organs* 2013;37:136-41.
- [9] Aebert H, Kirchner S, Keyser A, Birnbaum DE, Holler E, Andreesen R, Eissner G. et al. Endothelial apoptosis is induced by serum of patients after cardiopulmonary bypass. *Eur J Cardiothorac Surg* 2000;18:589-93.
- [10] Boyle EM, Pohlman TH, Johnson MC, Verrier ED. Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. *Ann Thorac Surg* 1997;63: 277-84.
- [11] Butler J, Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. *Ann Thorac Surg* 1993;55:552-9.
- [12] Engelman RM, Rousou JA, Flack JE 3rd, Deaton DW, Kalfin R, Das DK. Influence of steroids on complement and cytokine generation after cardiopulmonary bypass. *Ann Thorac Surg* 1995;60:801-4.
- [13] Cremer J, Martin M, Redl H, Bahrami S, Abraham C, Graeter T, Haverich A, Schlag G, Borst HG. Systemic inflammatory response syndrome after cardiac operations. *Ann Thorac Surg* 1996; 61:1714-20.

# Application of a Search Algorithm Using Stochastic Behaviors to Autonomous Control of a Ventricular Assist Device

Kentaro Ohnuma, Hirohito Sumikura, Akihiko Homma, Tomonori Tsukiya, Toshihide Mizuno, Yoshiaki Takewa and Eisuke Tatsumi,

**Abstract**— A ventricular assist device (VAD) is a device with mechanical pumps implanted adjacent to the patient's native heart to support the blood flow. Mechanical circulatory support using VADs has been an essential therapeutic tool for patients with severe heart failure waiting for a heart transplant in clinical site. Adaptive control of VADs that automatically adjust the pump output with changes in a patient state is one of the important approaches for enhanced therapeutic efficacy, prevention of complications and quality of life improvement. However adaptively controlling a VAD in the realistic situation would be difficult because it is necessary to model the whole including the VAD and the cardiovascular dynamics. To solve this problem, we propose an application of attractor selection algorithm using stochastic behavior to a VAD control system. In this study, we sought to investigate whether this proposed method can be used to adaptively control of a VAD in the simple case of a continuous flow VAD. The flow rate control algorithm was constructed on the basis of a stochastically searching algorithm as one example of application. The validity of the constructed control algorithm was examined in a mock circuit. As a result, in response to a low-flow state with the different causes, the flow rate of the pump reached a target value with self adaptive behavior without designing the detailed control rule based on the experience or the model of the control target.

## I. INTRODUCTION

A Ventricular Assist Device (VAD) is a device with mechanical pumps implanted adjacent to the patient's native heart to provide circulatory support (a left ventricular assist device, for example, pumps blood from the left ventricle to the aorta to assist blood flowing). Advanced hardware technology has enhanced the reliability of VAD long-term use, such as clinical application of implantable continuous flow VADs [1]. Accordingly, mechanical circulatory support using VADs has been an essential therapeutic tool for patients with severe heart failure waiting for a heart transplant [2]. On the other hand, considering about new treatment to recover cardiac function including destination therapy (DT) [3] or combination with myocardial regeneration therapy [4], there are many issues to solve, such as further device miniaturization, durability and antithrombogenicity

Research supported by Grants-in-Aid for Scientific Research B (no. 24390308) and Grant-in-Aid for Challenging Exploratory Research (no. 25670563) from the Japan Society for the Promotion of Science and the Ministry of Education, Culture, Sports, Science and Technology of Japan.

K. Ohnuma, H. Sumikura, T. Tsukiya, T. Mizuno, Y. Takewa, E. Tatsumi are with the National Cerebral and Cardiovascular Center Research Institute, Suita, Osaka 565-8565, Japan (corresponding author to provide phone: +81-6-6833-5012; fax: +81-6-6835-5406; e-mail: ohnuma.kentaro@ri.ncvc.go.jp).

A. Homma is with Tokyo Denki University, Hatoyama, Saitama 350-0394, Japan.

improvements, circulation-control abnormality regardless of the improved treatment effects and stable blood flow, and various complications. To solve these issues, advanced software functionality such as VAD drive control may be equally important as hardware improvements. Many researchers have conducted studies on bypass flow control using cardiovascular mathematical models as well as continuous flow VAD optimization such as development of a function to change rotation speed via synchronization with the patient's heart rate [5-8]. Variations in rotation speed are expected to produce clinical effects including cardiac function recovery and complication prevention. Some devices have been already equipped with control functions to prevent outflow sucking and maintain bypass blood flow. At clinical sites, however, devices are usually used in a fixed rate or rotation number. Major reasons that the VAD automatic control functions are not used in practice are because of the difficulties in long-term stable measurement of biological information and modeling of complex circulatory systems controlled by the autonomic nerve or humoral factors. An algorithmic error consequent to an unexpected complex circulation behavior may cause dangerous device operation. These problems are likely to be solved when VADs are equipped with flexibly adaptive control like human body.

A recent physiological study has demonstrated that searching behaviors based on noise (or fluctuations) including muscle molecular level movement and heart rate variability play an important role in human adaptability [9-13]. Moreover, some researchers attempted to apply this mechanism to artificial object control such as robots or communication systems [14-17]. The objective of the present study was to realize ventricular assist devices which flexibly can response to unexpected changes. The mechanism of human adaptive behaviors was used to enable VADs to deal with the situations in which accurate modeling was considered difficult. Furthermore, this study was conducted to propose the application of a searching algorithm to VAD control using stochastic behaviors and to verify the beneficial effects on VAD control by this method according to the results of flow control. As the first step to investigate the benefits of this proposed method, continuous flow pumps, simple systems, were used to perform mock circulation tests.

## II. MATERIALS AND METHODS

### A. Control Algorithm

Kashiwagi et al. proposed formula (1) called "attractor selection model" as a mathematical model to explain human sensing behaviors using noise [9].